Trader KillaXBT suggests Bitcoin has likely formed its cycle low for 2023, based on market structure rather than typical seasonal patterns that predict bottoms in the fourth quarter. The trader notes similarities between this year's market action and previous cycle lows, arguing that another low before year-end would not fit the established cycle structure. Recent market weakness is seen as de-risking following sharp declines in legacy markets, with crypto prices correlating. This view contrasts with seasonal timing, which has not yet aligned with expected patterns, and renewed selling has challenged the bullish outlook. Another analyst, Ahuja, also believes Bitcoin has passed its cycle low.
The story on Bitcoin's cycle low offers context for cryptocurrency market conditions. For readers following crypto, here is Pluang's market snapshot as of Nov 09, 2026 01:02 WIB: out of 50 major cryptocurrencies, 8 rose and 40 fell today. Notable movers include ZIL at Rp30 with a 1-day change of -4.27% and 74% sell order activity, KSM at Rp56,574 down 4.17%, and THETA at Rp2,532 down 4.09% with 79% buy order activity.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Parex Resources reported third-quarter results showing wider discounts and increased costs mainly due to one-time acquisition and optimization expenses. Despite these challenges, the company remains larger and more productive after recent acquisition...
